NCT03485417

Substance Misuse To Psychosis for Stimulants

Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 16 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.

Conditions

• Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)
• Schizophrenia and Related Disorders
• Stimulant Dependence
• Stimulant Abuse
• Pharmacotherapy

Interventions

Type	Name	Description
DRUG	Aripiprazole	for oral or depot preparation
DRUG	Paliperidone	for oral or depot
OTHER	Treatment as Usual	to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone

Timeline

• Start date: 2019-06-01
• Primary completion: 2024-05-31
• Completion: 2025-05-31
• First posted: 2018-04-02
• Last updated: 2026-03-27

Locations

1 site across 1 country: Hong Kong

Regulatory

• FDA-regulated drug study